Expression And Clinical Significance Of RACGAP1 In Hepatocellular Carcinoma

BackgroundPrimary liver cancer is a common digestive tract tumor in China and the most common pathological type is hepatocellular carcinoma that accounts for nearly 85-90%.According to the statistics of the National Cancer Center in 2015,the number of new cases of hepatocellular carcinoma reached about 365000,the incidence of which is second only to lung cancer,gastric cancer and colorectal cancer,seriously threating the physical and mental health of citizens.Nowadays.although the surgery,radiofrequency ablation,molecular targeted therapy,immunotherapy and other technologies continue to improve the therapeutic effect of hepatocellular carcinoma is not satisfactory,which the overall 5-year survival rate is still very low.Therefore,finding new biomarker related to the occurrence,development and prognosis of hepatocellular carcinoma is extremely important.RACGAP1 is one of the members of Rho GTP enzyme-activated protein family and is widely expressed in human.At present,it has been confirmed that RACGAP1 is highly expressed in a variety of malignant tumor tissues which is closely related to a variety of clinicopathological characteristics and poor prognosis.However,the expression and clinical significance of RACGAP1 in hepatocellular carcinoma is rarely reported in China.ObjectiveTo study the expression of RACGAP1 in hepatocellular carcinoma and to analyze the relationship between the expression of RACGAP1 and clinicopathological features and prognosis in hepatocellular carcinoma.Methods1.The expression level of RACGAP1 in hepatocellular carcinoma and adjacent normal tissues were detected by immunohistochemistry,and the relationship between the expression level of RACGAP1 in hepatocellular carcinoma and clinicopathological features were analyzed.2.The UALCAN online tool was used to analyse the relationship between RACGAP1 expression level and clinicopathological features of hepatocellular carcinoma from The Cancer Genome Atlas(TCGA).3.The GEPIA online tool was used to analyse the relationship between RACGAP1 expression level and prognosis of hepatocellular carcinoma from The Cancer Genome Atlas(TCGA).Results1.The results of Immunohistochemistry showed that the expression of RACGAP1 in hepatocellular carcinoma tissues was significantly higher than that in adjacent normal tissues(p<0.05)and the high expression of RACGAP1 were associated with TNM stages,pathological grade,tumor diameter of hepatocellular carcinoma patients(p<0.05).2.The results of UALCAN showed that the expression level of RACGAP1 in hepatocellular carcinoma tissues was significantly higher than that in normal liver tissues(p<0.05),and the high expression of RACGAP1 was associated with the TNM stage in hepatocellular carcinoma patients(p<0.05).3.The results of GEPIA showed that the overall survival rate of patients with high expression of RACGAP1 in hepatocellular carcinoma was significantly lower than that of patients with low expression(p<0.05).Conclusion1.The expression of RACGAP1 is significantly higher in hepatocellular carcinoma tissues than in paired adjacent normal tissues.2.The high expression of RACGAP1 is closely related to the TNM stage,pathological grade and tumor diameter in hepatocellular carcinoma patients which expected to be a potential biomarker for assessing the development of the hepatocellular carcinoma patients.3.The high expression of RACGAP1 in hepatocellular carcinoma indicated poor prognosis which expected to be a potential biomarker for assessing the prognosis of the hepatocellular carcinoma patients.